Munich, Germany

Heinz Hoefler

USPTO Granted Patents = 3 

Average Co-Inventor Count = 14.1

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2018

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Heinz Hoefler: Innovator in Cancer Treatment Prediction

Introduction

Heinz Hoefler is a notable inventor based in Munich, Germany. He has made significant contributions to the field of cancer treatment, particularly in predicting patient outcomes. With a total of 3 patents, his work has the potential to impact the lives of many patients suffering from cell proliferative disorders.

Latest Patents

Hoefler's latest patents include innovative methods for predicting the outcome of anthracycline treatment in patients with cell proliferative disorders. This invention focuses on determining the expression level of specific genes, including PITX2, TFF1, and PLAU. Additionally, he has developed methods for the prognosis of breast cancer, which involve modified genomic sequences and oligonucleotides for detecting the cytosine methylation state of genomic DNA. These advancements aim to predict disease-free survival and response to endocrine treatment in breast tissue disorders.

Career Highlights

Throughout his career, Heinz Hoefler has worked with prominent companies such as Epigenomics AG and Therawis Diagnostics GmbH. His experience in these organizations has allowed him to refine his expertise in the field of cancer research and diagnostics.

Collaborations

He has collaborated with esteemed colleagues, including John Foekens and Nadia Harbeck, to further advance research in cancer treatment and patient care.

Conclusion

Heinz Hoefler's contributions to cancer treatment prediction through his innovative patents highlight his dedication to improving patient outcomes. His work continues to pave the way for advancements in medical research and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…